Organization and Nature of Business (Details) |
3 Months Ended | 6 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
Dec. 21, 2020
USD ($)
shares
|
Dec. 16, 2020
D
$ / shares
shares
|
Jun. 30, 2021
USD ($)
$ / shares
shares
|
Mar. 31, 2021
USD ($)
|
Jun. 30, 2020
USD ($)
|
Mar. 31, 2020
USD ($)
|
Jun. 30, 2021
USD ($)
$ / shares
shares
|
Jun. 30, 2020
USD ($)
|
Dec. 31, 2020
USD ($)
|
|
| Subsidiary, Sale of Stock [Line Items] | |||||||||
| Warrants to purchase shares | shares | 172,500 | 172,500 | 172,500 | ||||||
| Warrants exercise price | $ / shares | $ 12.50 | $ 12.50 | $ 12.50 | ||||||
| Warrants exercise price percenatge of IPO Price | 125.00% | ||||||||
| Net loss | $ 4,282,962 | $ 3,056,033 | $ 654,585 | $ 466,553 | $ 7,338,995 | $ 1,121,138 | |||
| Net cash used in operating activities | 7,862,670 | $ 1,049,944 | |||||||
| Accumulated deficit | $ 35,304,100 | $ 35,304,100 | $ 27,965,105 | ||||||
| IPO | |||||||||
| Subsidiary, Sale of Stock [Line Items] | |||||||||
| Shares issued | shares | 3,450,000 | 3,000,000 | |||||||
| Share price | $ / shares | $ 10.00 | ||||||||
| Gross proceeds | $ 34,500,000 | ||||||||
| Net proceeds | $ 31,100,000 | ||||||||
| Underwriter option | |||||||||
| Subsidiary, Sale of Stock [Line Items] | |||||||||
| Shares issued | shares | 450,000 | ||||||||
| Days to purchase additional shares granted to underwriters | D | 45 | ||||||||
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash inflow from the additional capital contribution to the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Cash received on stock transaction after deduction of issuance costs. No definition available.
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks of a company. No definition available.
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Number of days to purchase additional shares to underwriters. No definition available.
|
| X | ||||||||||
- Definition Warrants exercise price as percentage of initial public offering price No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|